Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(2):120-122
DOI: 10.5428/pcar20180210
Definition and prevention of substandard/spurious/falsely labelled/falsified and counterfeit medicines
1. WANG Meng1(1.Teaching Office of Health Statistics,Faculty of Health Service,Second Military Medical University,Shanghai 200433,China 1207763813@qq.com)
2. YE XiaoFei1(1.Teaching Office of Health Statistics,Faculty of Health Service,Second Military Medical University,Shanghai 200433,China )
3. FENG HongYun2(2.Center of Drug Evaluation,China Food and Drug Administration,Beijing 100045,China )
4. HOU YongFang2(2.Center of Drug Evaluation,China Food and Drug Administration,Beijing 100045,China )
5. GUO XiaoJing1(1.Teaching Office of Health Statistics,Faculty of Health Service,Second Military Medical University,Shanghai 200433,China )
6. HE Jia1(1.Teaching Office of Health Statistics,Faculty of Health Service,Second Military Medical University,Shanghai 200433,China hejia@smmu.edu.cn)
ABSTRACT  Governments around the globe are faced with the hard problem in the control of substandard/spurious/falsely labeled/falsified and counterfeit (SSFFC) medicines.However,at present,there is no unified definition on the matter,which is unfavorable to the control of SSFFC medicines globally.In this paper,we use such technical terms as SSFFC medical products to define what used to be widely known as “counterfeit medicine”.At the same time,we also introduce the harms and control measures for SSFFC drugs,so as to provide reference for drug supervision and surveillance.
Welcome to PCAR! You are the number 292 reader of this article!
Please cite this article as:
WANG Meng1,YE XiaoFei1,FENG HongYun2,HOU YongFang2,GUO XiaoJing1,HE Jia1,. Definition and prevention of substandard/spurious/falsely labelled/falsified and counterfeit medicines[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(2): 120-122.
References:
1. ZHAO Jian,SHAO Rong.Sample interpretation of definition of adulterated drug and misbranded drug in Drug Management Law[J].Prog Pharm Sci,2004,28(8):379-381.In Chinese with English title.
2. WHO.Frequently asked questions[EB/OL].(2011-07-19)[2017-03-02].http://www.who.int/medicines/services/counterfeit/faqs/QandAsUpdateJuly11.pdf?ua=1.
3. WHO.WHO Expert Committee on the specifications for pharmaceutical preparations:forty-fourth report [EB/OL].(2015-11-09)[2017-03-02].http://www.who.int/medicines/publications/TRS957_2010.pdf?ua=1.
4. YE PeiYun,ZHU XiaoHui,YE Hua.Comparison on the definitions of counterfeit or substandard drugs in several countries throughout the world[J].Chin Pharm Aff,2012,26(10):1066-1069.In Chinese with English abstract.
5. Regulations for the management of drug instructions and labels (No.24 decree by CFDA)[EB/OL].(2006-03-15)[2017-03-02].http://www.sda.gov.cn/WS01/CL0053/24522.html.In Chinese.
6. Smith B J A,Naughton B,Kramm A,et al.EU falsified medicines directive:requirements and implications for multi-stakeholder healthcare delivery[EB/OL].(2015-12-08)[2017-03-02].http://www.raps.org/uploadedFiles/Site_Setup/Store/RAC_Prep_Resources(1)/EU_Fundamentals_7thEd_Sam-ple_Chapter.pdf.
7. The war against counterfeit pharmaceuticals-take the case of African Nigeria as an example[D].Qingdao:Ocean University of China,2014.In Chinese.
8. ZHENG KaiYi,HU YuZhu.Role of pharmaceutical analysis technique in pharmacovigilance[J].Prog Pharm Sci,2008,32(5):216-222.In Chinese with English abstract.
9. JIANG Jing,HOU YongFang,LIU XiuJuan,et al.Application of different signal detection methods in Chinese spontaneous reporting adverse drug reactions system[J].Chin J Pharmacovigil,2010,7(3):154-155.In Chinese with English abstract.
10. LU ChangFei,TIAN YueJie.Exploration in the use of cluster analysis method in adverse drug reaction monitoring:based on clindamycin hydrochloride injection adverse reaction monitoring data[J].Chin J Pharmacovigil,2014,11(1):27-30.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口